A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression - PubMed (original) (raw)
Affiliations
- PMID: 7805040
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
D H Harpole Jr et al. Cancer Res. 1995.
Abstract
In order to construct a multivariate model for predicting early recurrence and cancer death for patients with stage I non-small cell lung cancer, 271 consecutive patients (mean age, 63 +/- 8 years) who were diagnosed, treated, and followed at one institution were studied. All patients were clinical stage I with head and chest/abdominal computed tomograms and radionuclide bone scans without evidence of metastatic disease. Pathological material after resection was reviewed to verify histological staging. Follow-up documented the time and location of any recurrence, was a median 56 months in duration, and was complete in all cases. Data recorded included age, sex, smoking history, presenting symptoms, pathological description, and oncoprotein staining for erbB-2 (HER-2/neu), p53, and KI-67 proliferation protein. Immunohistochemistry of oncogene expression was performed on two separate archived paraffin tumor blocks for each patient, with normal lung as control. All analyses were blinded and included Kaplan-Meier survival estimates with Cox proportional hazards regression modeling. Data, including immunohistochemistry, were complete for all 271 patients. Actual 5-year survival was 63% and actuarial 10-year survival was 58%. Significant univariate predictors (P < 0.05) of early recurrence and cancer-death were: male sex; the presence of symptoms; chest pain; type of cough; hemoptysis; tumor size > 3 cm diameter (T2); poor differentiation; vascular invasion; erbB-2 expression; p53 expression; and a higher KI-67 proliferation index (> 5%). An additive oncogene expression curve demonstrated a 5-year survival of 72% for 136 patients without p53 or erbB-2, 58% for 108 patients who expressed either oncogene, and 38% for 27 who expressed both (P < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
Harpole DH Jr, Marks JR, Richards WG, Herndon JE 2nd, Sugarbaker DJ. Harpole DH Jr, et al. Clin Cancer Res. 1995 Jun;1(6):659-64. Clin Cancer Res. 1995. PMID: 9816029 - [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y, Zhang XR, Fu J, Tan W, Zhang W. Wang Y, et al. Zhonghua Zhong Liu Za Zhi. 2004 Jun;26(6):369-72. Zhonghua Zhong Liu Za Zhi. 2004. PMID: 15312350 Chinese. - Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicoló G, Perdelli L, Stampino CG, Rosso R, Puntoni R. Ardizzoni A, et al. Cancer. 2001 Oct 1;92(7):1896-904. Cancer. 2001. PMID: 11745263 - [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K, Ishida H, Furukawa T, Koyanagi K, Miyamoto Y. Irie K, et al. Rinsho Byori. 1996 Jan;44(1):32-41. Rinsho Byori. 1996. PMID: 8691638 Review. Japanese. - p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
Haque AK, Adegboyega P, Al-Salameh A, Vrazel DP, Zwischenberger J. Haque AK, et al. Mod Pathol. 1999 Dec;12(12):1158-66. Mod Pathol. 1999. PMID: 10619270 Review.
Cited by
- Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.
Janik A, Torrente M, Costabello L, Calvo V, Walsh B, Camps C, Mohamed SK, Ortega AL, Nováček V, Massutí B, Minervini P, Campelo MRG, Del Barco E, Bosch-Barrera J, Menasalvas E, Timilsina M, Provencio M. Janik A, et al. JCO Clin Cancer Inform. 2023 Jul;7:e2200062. doi: 10.1200/CCI.22.00062. JCO Clin Cancer Inform. 2023. PMID: 37428988 Free PMC article. - Deep Learning with Multimodal Integration for Predicting Recurrence in Patients with Non-Small Cell Lung Cancer.
Kim G, Moon S, Choi JH. Kim G, et al. Sensors (Basel). 2022 Aug 31;22(17):6594. doi: 10.3390/s22176594. Sensors (Basel). 2022. PMID: 36081053 Free PMC article. - Prediction of Target-Drug Therapy by Identifying Gene Mutations in Lung Cancer With Histopathological Stained Image and Deep Learning Techniques.
Huang K, Mo Z, Zhu W, Liao B, Yang Y, Wu FX. Huang K, et al. Front Oncol. 2021 Apr 13;11:642945. doi: 10.3389/fonc.2021.642945. eCollection 2021. Front Oncol. 2021. PMID: 33928031 Free PMC article. - Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades.
Bar J, Urban D, Amit U, Appel S, Onn A, Margalit O, Beller T, Kuznetsov T, Lawrence Y. Bar J, et al. J Oncol. 2021 Jan 12;2021:7836264. doi: 10.1155/2021/7836264. eCollection 2021. J Oncol. 2021. PMID: 33519934 Free PMC article. - Mutated p53 Promotes the Symmetric Self-Renewal of Cisplatin-Resistant Lung Cancer Stem-Like Cells and Inhibits the Recruitment of Macrophages.
Xu Y, Xu Z, Li Q, Guo L, Wang Y, Zhou J, Wang G, Liu Y. Xu Y, et al. J Immunol Res. 2019 Oct 31;2019:7478538. doi: 10.1155/2019/7478538. eCollection 2019. J Immunol Res. 2019. PMID: 31781681 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous